

Medical Coverage Policy | Total Artificial Hearts as Permanent Replacement Therapy



EFFECTIVE DATE: 11/06/2007
POLICY LAST UPDATED: 03/04/2014

OVERVIEW

This medical policy documents coverage for Total Artificial Hearts as Permanent Replacement Therapy. The total artificial heart (TAH) replaces the native ventricles and is attached to the pulmonary artery and aorta; the native heart is typically removed. TAH may be used as a bridge to heart transplantation or as destination therapy in those who are not candidates for transplantation.

PRIOR AUTHORIZATION

Prior authorization is not required.

POLICY STATEMENT

Blue CHiP for Medicare:

The implantation of total artificial hearts is considered medically necessary for BlueCHiP for Medicare members when the member is enrolled in a CMS approved clinical study that is listed at the following website: http://www.cms.hhs.gov/MedicareApprovedFacilitie/06_artificialhearts.asp#TopOfPage

Medicare policy is developed separately from BCBSRI policy. Medicare policy incorporates consideration of governmental regulations from CMS (Centers for Medicare and Medicaid Services), such as national coverage determinations or local coverage determinations. In addition to benefit differences, CMS may reach different conclusions regarding the scientific evidence than does BCBSRI. Medicare and BCBSRI policies may differ. However, BlueCHiP for Medicare members must be offered, at least, the same services as Medicare offers.

Commercial Products:

Total artificial hearts with FDA-approved devices may be considered medically necessary as a bridge to heart transplantation for patients with biventricular failure who have no other reasonable medical or surgical treatment options, who are ineligible for other univentricular or biventricular support devices, and are currently listed as heart transplantation candidates or are undergoing evaluation to determine candidacy for heart transplantation, and not expected to survive until a donor heart can be obtained.

The implantation of total artificial hearts as permanent replacement therapy is considered **not** medically necessary as there is insufficient peer reviewed scientific literature that demonstrates that the procedure/service is effective.

The use of non-FDA approved or cleared implantable ventricular assist devices or total artificial hearts is considered non-covered.

MEDICAL CRITERIA

Not Applicable

BACKGROUND

The total artificial heart (TAH) replaces the native ventricles and is attached to the pulmonary artery and aorta; the native heart is typically removed. TAH may be used as a bridge to heart transplantation or as destination therapy in those who are not candidates for transplantation.

Heart failure may be the consequence of a number of differing etiologies, including ischemic heart disease, cardiomyopathy, congenital heart defects, or rejection of a heart transplant. The reduction of cardiac output is considered to be severe when systemic circulation cannot meet the body's needs under minimal exertion. Heart transplantation improves quality of life and has survival rates at 1, 5, and 10 years of 88%, 74%, and 55%, respectively. (1) The supply of donor organs has leveled off, while candidates for transplants are increasing, compelling the development of mechanical devices.

Initial research into mechanical assistance for the heart focused on the total artificial heart, a biventricular device which completely replaces the function of the diseased heart. An internal battery required frequent recharging from an external power source. Many systems utilize a percutaneous power line, but a transcatheter power-transfer coil allows for a system without lines traversing the skin, possibly reducing the risk of infection. Because the heart must be removed, failure of the device is synonymous with cardiac death.

In October 2004, device CardioWest™ Temporary Total Artificial Heart (SynCardia Systems, Inc., Tucson, AZ) was approved by the U.S. Food and Drug Administration (FDA) through the premarket approval process for use as a bridge to transplant in cardiac transplant-eligible candidates at risk of imminent death from biventricular failure. Also, the temporary CardioWest™ Total Artificial Heart (TAH-t) is intended for use inside the hospital. In April 2010, the FDA approved a name-change to Syncardia Temporary Total Artificial Heart.

In September 2006, device AbioCor® Implantable Replacement Heart System (AbioMed, Inc., Danvers MA) was approved by the FDA through the Humanitarian Device Exemption (HDE) process for use in severe biventricular end-stage heart disease individuals who are not cardiac transplant candidates and who:

- are younger than 75 years of age
- require multiple inotropic support
- are not treatable by left ventricular assist devices (LVAD) destination therapy; and
- are not weanable from biventricular support if on such support.

In addition to meeting other criteria, patients who are candidates for the AbioCor® TAH must undergo a screening process to determine if their chest volume is large enough to hold the device. The device is too large for approximately 90% of women and for many men.

There is a smaller amount of evidence on the use of TAH as a bridge to transplantation, or as destination therapy. The type of evidence on bridge to transplant is similar to that for left ventricular assist devices (LVADs), i.e., case series reporting substantial survival rates in patients without other alternatives. Therefore, this evidence is sufficient to conclude that TAH improves outcomes for these patients similar to LVADs, and is a reasonable alternative for patients who require bridge to transplantation but who are ineligible for other types of support devices. There is insufficient evidence to support the use of TAH as destination therapy, therefore TAH as a destination therapy is considered not medically necessary for commercial members. For BlueCHiP for Medicare members, TAH as a destination therapy is covered when the member is enrolled in a CMS approved clinical study.

COVERAGE

Benefits may vary between groups/contracts. Please refer to the appropriate Evidence of Coverage, Subscriber Agreement for applicable surgery services, and not medically necessary coverage.

CODING

Blue CHiP for Medicare

The following codes may be considered medically necessary when used as total heart replacement when the member is enrolled in a CMS approved clinical study; for correct claims processing append modifier Q0 - Investigational clinical service provided in a clinical research study that is in an approved clinical research study.

0051T **0052T** **0053T**

Commercial Products:

The following codes are considered not medically necessary when used as total heart replacement:

0051T **0052T** **0053T**

RELATED POLICIES

None

PUBLISHED

Provider Update May 2014

Provider Update Aug 2013

Provider Update July 2012

Provider Update Dec 2011

Provider Update Mar 2010

Provider Update Apr 2009

Policy Update Jan 2008

REFERENCES

1. US Department of Health and Human Services. U.S. Organ Procurement and Transplantation Network (OPTN) and the Scientific Registry of Transplant Recipients (SRTR). 2008 OPTN/SRTR Annual Report 1998-2007. Available online at <http://optn.transplant.hrsa.gov/ar2008/>.
2. Davies RR, Russo MJ, Hong KN et al. The use of mechanical circulatory support as a bridge to transplantation in pediatric patients: an analysis of the United Network for Organ Sharing database. *J Thorac Cardiovasc Surg* 2008; 135(2):421-7, 27 e1.
3. NCD for Artificial Hearts and Related Devices (20.9). Publication # 100-3:http://www.cms.hhs.gov/mcd/viewncd.asp?ncd_id=20.9&ncd_version=3&basket=ncd%3A20%2E9%3A3%3AArtificial+Hearts+and+Related+Devices

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

